The clinical effectiveness of pneumococcal vaccination:
Identifieur interne : 000D61 ( Istex/Curation ); précédent : 000D60; suivant : 000D62The clinical effectiveness of pneumococcal vaccination:
Auteurs : David S. Fedson [France]Source :
- Vaccine [ 0264-410X ] ; 1999.
Abstract
Randomized controlled trials have shown that pneumococcal polysaccharide vaccine is efficacious in preventing pneumococcal bacteraemia and pneumococcal pneumonia in young adults. Clinical trials in older adults, however, have been inconclusive, usually because the studies have been too small. Retrospective studies have shown that pneumococcal vaccination is approximately 50–80% effective in preventing invasive pneumococcal disease among older persons. Vaccination in this age group is also very cost-effective. These findings are the basis for the recent expansion of immunisation policies and the growth in vaccine use in many developed countries. Serologic and clinical studies, however, suggest that vaccine-induced protection declines after 3–5 years, leading to widespread concern about the need for routine revaccination. Because pneumococcal polysaccharide vaccine does not induce immunologic memory, the benefits of revaccination can also be expected to be relatively short-lasting. Alternative strategies of immunological priming of adults with pneumococcal conjugate vaccine followed by boosting with polysaccharide vaccine, or perhaps vaccination with one of the newer protein vaccines, should be considered. Because these new generation pneumococcal vaccines could provide a foundation of life-long protection against pneumococcal infection, their widespread use among adults could have an immense impact on public health worldwide.
Url:
DOI: 10.1016/S0264-410X(99)00113-9
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D63
Links to Exploration step
ISTEX:4C531E294B3C7FC0EFA31203E7EFDF5B36808983Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The clinical effectiveness of pneumococcal vaccination:</title><author><name sortKey="Fedson, David S" sort="Fedson, David S" uniqKey="Fedson D" first="David S" last="Fedson">David S. Fedson</name><affiliation wicri:level="1"><mods:affiliation>Pasteur Mérieux MSD, 8 rue Jonas Salk, 69367, Lyon, cedex 07, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pasteur Mérieux MSD, 8 rue Jonas Salk, 69367, Lyon, cedex 07</wicri:regionArea></affiliation><affiliation><mods:affiliation>E-mail: fedson@fr.pmmsd.com</mods:affiliation><wicri:noCountry code="no comma">E-mail: fedson@fr.pmmsd.com</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4C531E294B3C7FC0EFA31203E7EFDF5B36808983</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1016/S0264-410X(99)00113-9</idno><idno type="url">https://api.istex.fr/document/4C531E294B3C7FC0EFA31203E7EFDF5B36808983/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D63</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000D63</idno><idno type="wicri:Area/Istex/Curation">000D61</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">The clinical effectiveness of pneumococcal vaccination:</title><author><name sortKey="Fedson, David S" sort="Fedson, David S" uniqKey="Fedson D" first="David S" last="Fedson">David S. Fedson</name><affiliation wicri:level="1"><mods:affiliation>Pasteur Mérieux MSD, 8 rue Jonas Salk, 69367, Lyon, cedex 07, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pasteur Mérieux MSD, 8 rue Jonas Salk, 69367, Lyon, cedex 07</wicri:regionArea></affiliation><affiliation><mods:affiliation>E-mail: fedson@fr.pmmsd.com</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1999">1999</date><biblScope unit="volume">17</biblScope><biblScope unit="supplement">S1</biblScope><biblScope unit="page" from="S85">S85</biblScope><biblScope unit="page" to="S90">S90</biblScope></imprint><idno type="ISSN">0264-410X</idno></series><idno type="istex">4C531E294B3C7FC0EFA31203E7EFDF5B36808983</idno><idno type="DOI">10.1016/S0264-410X(99)00113-9</idno><idno type="PII">S0264-410X(99)00113-9</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Randomized controlled trials have shown that pneumococcal polysaccharide vaccine is efficacious in preventing pneumococcal bacteraemia and pneumococcal pneumonia in young adults. Clinical trials in older adults, however, have been inconclusive, usually because the studies have been too small. Retrospective studies have shown that pneumococcal vaccination is approximately 50–80% effective in preventing invasive pneumococcal disease among older persons. Vaccination in this age group is also very cost-effective. These findings are the basis for the recent expansion of immunisation policies and the growth in vaccine use in many developed countries. Serologic and clinical studies, however, suggest that vaccine-induced protection declines after 3–5 years, leading to widespread concern about the need for routine revaccination. Because pneumococcal polysaccharide vaccine does not induce immunologic memory, the benefits of revaccination can also be expected to be relatively short-lasting. Alternative strategies of immunological priming of adults with pneumococcal conjugate vaccine followed by boosting with polysaccharide vaccine, or perhaps vaccination with one of the newer protein vaccines, should be considered. Because these new generation pneumococcal vaccines could provide a foundation of life-long protection against pneumococcal infection, their widespread use among adults could have an immense impact on public health worldwide.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D61 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000D61 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:4C531E294B3C7FC0EFA31203E7EFDF5B36808983
|texte= The clinical effectiveness of pneumococcal vaccination:
}}
| This area was generated with Dilib version V0.6.29. |  |